September 14, 2018
CADTH and INESSS are introducing a new pilot project, whereby both organizations will jointly establish and consult a panel of clinical specialists on selected drug products. This pilot will enable a broad base of clinical specialists to provide greater insight for a therapy under review and help “integrate pan-Canadian expertise into the review processes for drugs that are likely to be associated with complex evaluations and challenging deliberations”. This joint panel of specialists can also help identify implementation challenges and provide greater insight into the clinical management of patients living with a certain condition. As a result, CADTH and INESSS hope to reduce duplication of effort in their health technology assessment processes.
While the same panel of clinical specialists will be consulted by both organizations, CADTH and INESSS will continue to work independently on their respective review processes. The drugs for this pilot have not yet been selected but manufacturers will be notified in writing if their drug has been identified for inclusion (without any disruption to the review timelines). Drugs reviewed through pCODR will not be part of this pilot.
For more information, please contact Marla Weingarten.